Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04267874
Other study ID # OSU-19007
Secondary ID NCI-2020-00418
Status Completed
Phase Early Phase 1
First received
Last updated
Start date October 25, 2019
Est. completion date June 13, 2021

Study information

Verified date November 2023
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies how well black raspberry nectar works in changing the gut microbiome and in reducing inflammatory processes that may lead to lung cancer. Studying the effects of black raspberry beverage on inflammation may help doctors find strategies to reduce the risk of developing lung cancer.


Description:

PRIMARY FEASIBILITY OBJECTIVE: I. To evaluate the feasibility of establishing a diet intervention trial with longitudinal microbiome collection in Ohio State University Comprehensive Cancer Center (OSUCCC) Lung Cancer Screening Clinic (OSUCCC-LCSC). PRIMARY SCIENTIFIC OBJECTIVE: I. To determine the impact of the black raspberry (BRB) nectar intervention on the microbiome and inflammatory biomarkers. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive BRB nectar orally (PO) twice daily (BID) for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10. ARM II: Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date June 13, 2021
Est. primary completion date May 13, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 77 Years
Eligibility Inclusion Criteria: - Have a 30 pack-year smoking history - Be either a current smoker or a former smoker that quit in the last 15 years. Any individual who is currently smoking and has smoked more than 100 cigarettes in their lifetime will be identified as a current smoker - Agree to consume a standardized vitamin / mineral supplement and avoid other nutritional, dietary or alternative medications / supplements / probiotics for the duration of the study - Agree to follow a berry-free / controlled phenolic diet and to document consumption of polyphenolic foods each day of the study using a simple daily form Exclusion Criteria: - Person has an allergy to any berries, pectin, or food colorants apples,as well as kiwi fruit, strawberries, soy sauce, pine nuts, almonds, cherries, peaches, blackberries, pears - Person states that they are not a: - Current smoker: active cigarette smoker who has smoked more than 30 pack-years in the last 15 years OR - Former smoker: not a current smoker active cigarette smoker who has smoked more than 30 pack years in the last 15 years - Person is unwilling to follow a berry-free/controlled polyphenol diet while on study - Person has history of metabolic disorders (diabetes, hyper/hypo-thyroidism, etc.); digestive illness which may result in nutrient malabsorption (Crohn's disease, Celiac, renal/hepatic insufficiency, short bowel, etc.); disorders that affect connective tissues; or blood clotting disorders - Person has allergy or food intolerance to ingredients in study products (black raspberries or other berries) - Person is on a regimen of any of the following medications: - Immunosuppressants, bisphosphonates, or steroids. - Anticoagulants (warfarin, apixaban, dabigatran, and rivaroxaban) - Probiotics - Person is undergoing treatment for cancer in any form - Person is currently pregnant or nursing or plans to become pregnant during this study - Person plans to enter smoking cessation or change their smoking status during the course of the study

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Biospecimen Collection
Undergo collection of nasal swabs, blood, urine, and stool
Dietary Supplement:
Nutritional Supplementation
Given black raspberry nectar PO
Drug:
Placebo Administration
Given PO
Other:
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rates Recruitment rates will be defined as the proportion of screened accrued relative to those approached. Successful recruitment rates will be defined as >= 10% of participants approached agree to participate. Up to 3 years
Primary Study adherence Study adherence will be defined as the percent of the biospecimens collected at the end of the study period, with a compliance goal of 60%. Will track the monthly collection of data and document reasons for missing any scheduled collection dates. The proportions of missing information at each time point will be calculated. Descriptive statistics will examine the distribution of all patient and treatment characteristics, overall and by patient and disease characteristics. Up to 3 years
Primary Inflammatory markers found in nasal brushings Evaluated by ribonucleic acid sequencing. Up to 3 years
Primary Changes in stool microbe relative abundances Evaluated by metagenomic whole sequencing. Up to 3 years
Primary Biologic responses to the black raspberry (BRB) nectar Samples of urine, stool. and blood will be analyzed for BRB phytochemicals (ellagitannins, ellagic acid, quercetin glycosides, anthocyanins) and their metabolites (urolithins, quercetin glucuronides/sulfates, methylated anthocyanins). Up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04931017 - Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer Phase 2
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Not yet recruiting NCT06038526 - Evaluation of Canakinumab in High-Risk Former-Smokers Phase 2
Terminated NCT02856581 - Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes Phase 3
Completed NCT04922697 - Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study N/A
Recruiting NCT04644952 - The Rise in Robotic Atypical Segmentectomies
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05407168 - Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool N/A
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT03709953 - Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma Phase 2
Active, not recruiting NCT03267524 - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT02237183 - Iloprost in Preventing Lung Cancer in Former Smokers Phase 1
Recruiting NCT04783168 - Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study N/A
Completed NCT04635761 - Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening N/A
Active, not recruiting NCT03164486 - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide Early Phase 1
Recruiting NCT05802186 - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study N/A
Active, not recruiting NCT01696968 - Screening for Lung Cancer in Older Patients (PLCO Screening Trial) N/A
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Recruiting NCT04969341 - Improving Lung Cancer Screening Adherence by Overcoming Barriers for Vulnerable Populations

External Links